Use of Almitrine and Inhaled Nitric Oxide in ARDS Due to COVID-19.

ABSTRACT: Introduction: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is manifested by an acute respiratory distress syndrome (ARDS) with intense inflammation and endothelial dysfunction leading to particularly severe hypoxemia. We hypothesized that an impaired hypoxic pulmonary vasoconstriction aggravates hypoxemia. The objective of the study was to test the effect of two pulmonary vasoactive drugs on patient oxygenation. Methods: Observational, single-center, open-label study in one intensive care unit (ICU) of the Paris area, realized in April 2020. Eligible patients had coronavirus disease 2019 (COVID-19) and moderate to severe ARDS [arterial partial pressure of oxygen/fraction of inspired oxygen (PaO₂/FiO₂) <200 mmHg] despite conventional prote

SUBMITTER: Laghlam D 

PROVIDER: S-EPMC8280335 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature